ClinicalTrials.gg
RecruitingNCT07544589Updated Oct 5, 2026

A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers

A Phase 1 interventional study of DISP-10 in Colorectal Cancer, Gastric Adenocarcinoma and Esophageal Adenocarcinoma, sponsored by Dispatch Biotherapeutics. Recruiting at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Dispatch Biotherapeutics · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.
Updated Oct 5, 2026Eligibility revised2 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
66
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 2,342 studies in Colorectal Neoplasms with a site in United States — 415 open to participants now, 629 under way, 30 of them phase 3. Colorectal Neoplasms · United States.

Planned enrollment
949th of 1,934
66 · median 64
Started
2026
with 119 others
Phase 1
551 of 2,342
99 open now
Primary completion
2046-04
later than 627 of 627 live
Registered
2,274th of 2,342
by date

Among the 2,342 studies in Colorectal Neoplasms with a site in United States, this one is the 949th largest by planned enrollment of the 1,934 interventional ones that give a count, is one of 120 that started in 2026, is one of 551 in phase 1, reaches primary completion later than 627 of the 627 other live ones, and was the 2,274th registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

415 of the 2,342 studies in Colorectal Neoplasms with a site in United States are open now. Recruiting first, the newest first:

410 more — sign in →

All 415 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,342 studies in Colorectal Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 1, multicenter, open-label study of DISP-10, a combination therapy consisting of DV-10 (adenovirus) and idecabtagene vicleucel (ide-cel, BCMA-directed chimeric antigen receptor [CAR] T), in adult participants with advanced gastrointestinal (GI) cancers.

The study will consist of 2 parts: dose-escalation (Part 1) and dose-expansion (Part 2). Part 1 of the study will evaluate the safety and tolerability of increasing dose levels of DISP-10 to establish the recommended dose for expansion (RDE); Part 2 will evaluate the safety and efficacy of DISP-10 in participants treated at the RDE.

03

Conditions studied

  • Colorectal Cancer
  • Gastric Adenocarcinoma
  • Esophageal Adenocarcinoma
  • Gastroesophageal Adenocarcinoma
  • Biliary Tract Carcinoma

Keywords

  • CAR T
  • Adenovirus
  • ABECMA
  • BCMA
  • gastrointestinal cancer
  • CAR-T
04

Who can participate

The criteria were revised on the registry on Oct 5, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. confirmed advanced or esophageal, gastroesophageal junction, gastric adenocarcinoma, colorectal adenocarcinoma, or biliary tract carcinoma
  2. according to v1.1 and at least 1 additional site of disease amenable to
  3. (ECOG) performance status 0 or 1
  4. Aged ≥18 years at time of signing
  5. Adequate organ function

Key Exclusion Criteria:

  1. Previous solid organ or hematopoietic cell transplant
  2. Evidence of rapid disease progression, defined as radiographic or clinical progression within 3 months of the most recent
  3. Known history of or infection
  4. Previous or concurrent except if curatively treated more than 3 years prior to enrollment
  5. Known active central nervous system (CNS) metastases
  6. pleural or pericardial effusion or peritoneal carcinomatosis
  7. Active treatment with antiviral agents
  8. History of severe to fludarabine or cyclophosphamide
  9. Prior therapies/treatments with oncolytic viruses or T cell derived cellular therapy

Additional criteria apply and should be discussed with the study site.

Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
66 participants (estimated)

Study arms

  • Experimental
    DISP-10

    Participants will receive DV-10 in combination with ide-cel. Lymphodepleting chemotherapy (fludarabine and cyclophosphamide) will be administered a few days prior to ide-cel.

    Biological: DISP-10

Interventions

  • BiologicalDISP-10

    Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) to produce ide-cel. During ide-cel production, participants may receive bridging therapy for disease control per Investigator discretion. DV-10 administration will be followed by lymphodepleting chemotherapy (fludarabine and cyclophosphamide) and subsequent ide-cel administration.

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment Emergent Adverse Events (TEAEs)

    Graded using National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE) v6.0

    Time frame: 90 days (2 years for related Serious Adverse Events)

  2. Incidence of Dose Limiting Toxicities (DLTs) [PART 1]

    Graded using National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE) v6.0

    Time frame: 28 days

  3. Identification of the Recommended Dose for Expansion (RDE) [PART 1]

    To select the Recommended Dose for Expansion (RDE) for Part 2

    Time frame: Up to 2 years

  4. Overall response rate (ORR) [PART 2]

    Confirmed complete response (CR) or partial response (PR), per RECIST v1.1

    Time frame: Up to 2 years

Secondary outcomes

  1. Overall response rate (ORR) [PART 1]

    Confirmed CR or PR, per RECIST v1.1

    Time frame: Up to 2 years

  2. Disease control rate (DCR)

    Proportion of participants with CR, PR, or stable disease per RECIST v1.1

    Time frame: Up to 2 years

  3. Duration of response (DOR)

    Time from CR or PR to radiographic progression or death

    Time frame: Up to 2 years

  4. Progression Free Survival (PFS)

    Time from ide-cel administration to disease progression or death, whichever occurs first

    Time frame: Up to 2 years

  5. Overall survival (OS)

    Time from ide-cel administration to death

    Time frame: Up to 15 years

  6. Time to response (TTR)

    Time from ide-cel administration to the first documentation of objective tumor response

    Time frame: Up to 2 years

  7. Cellular kinetics (CK) of ide-cel

    Measurement of ide-cel CK in the blood

    Time frame: Up to 2 years

  8. Pharmacokinetics of DV-10 - Cmax

    Maximum concentration in blood

    Time frame: Up to 2 years

  9. Pharmacokinetics of DV-10 - Tmax

    Time to maximum concentration in blood

    Time frame: Up to 2 years

  10. Pharmacokinetics of DV-10 - AUC

    Area under the blood concentration curve

    Time frame: Up to 2 years

07

Study locations

6 of 7 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Apr 2046, 240 months after the start.

Of 269 industry-sponsored phase 1 interventional studies under Colorectal Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 66. This study's planned 240 months is above that.

Counting every sponsor, half of 435 studies reached it within 48 months; a quarter within 31 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2026
First posted
Apr 22, 2026
StartActual
Apr 13, 2026
Primary completionEst.
Apr 2046
CompletionEst.
Apr 2046
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added
Show 2 added (2 United States)
  • Moffitt Cancer Center · Tampa, United States
  • Huntsman Cancer Institute · Salt Lake City, United States
Oct 5, 2026
Eligibility
1 criterion edited, 1 added
What changed in the criteria
  • EditedHistologically confirmed advanced or metastatic esophageal, gastroesophageal junction, gastric adenocarcinoma, or colorectal adenocarcinoma, or biliary tract carcinoma
  • AddedAdditional criteria apply and should be discussed with the study site.
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    2 sites added
    Show 2 added (2 United States)
    • Moffitt Cancer Center · Tampa, United States
    • Huntsman Cancer Institute · Salt Lake City, United States
    Eligibility 1 criterion edited, 1 added
    What changed in the criteria
    • EditedHistologically confirmed advanced or metastatic esophageal, gastroesophageal junction, gastric adenocarcinoma, or colorectal adenocarcinoma, or biliary tract carcinoma
    • AddedAdditional criteria apply and should be discussed with the study site.
    + 2 other changes: verification date and conditions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07544589
Lead sponsor
Dispatch Biotherapeutics
Responsible party
Sponsor
First posted
Apr 22, 2026
Start date
Apr 13, 2026
Primary completion
Apr 2046 (estimated)
Completion
Apr 2046 (estimated)
Last update
Oct 5, 2026

Study contacts

Dispatch Clinical
Contact
clinicaltrials@dispatchbio.com
(215) 792-4699

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion